Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases
- 27 May 2017
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 37 (8) , 2169-2178
Abstract
The objective of this study was to investigate the clinical significance of the Wnt/β-catenin signaling pathway in glucocorticoid-induced osteoporosis. A total of 91 patients with systemic autoimmune diseases who received initial glucocorticoid therapy with prednisolone (30–60 mg daily) were prospectively enrolled. We measured serum levels of N-terminal peptide of type I procollagen (P1NP), bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase isoform 5b (TRACP-5b), N-telopeptide cross-linked type I collagen (NTX), sclerostin, Dickkopf-1 (Dkk-1), and Wnt3a before starting glucocorticoid therapy and every week for 4 weeks after its initiation. The effects of dexamethasone on expression of mRNA and protein of sclerostin and Dkk-1 by cultured normal human osteoblasts (NHOst) were evaluated by RT-PCR and ELISA, respectively. Serum levels of sclerostin and Dkk-1 increased significantly by 1 week of glucocorticoid therapy and then decreased from the second week onward. Serum Wnt3a tended to decrease and serum P1NP showed a significant decrease. However, TRACP-5b was significantly elevated from the first week of treatment onwards. In vitro study, dexamethasone increased Dkk-1 mRNA expression in cultured NHOst, but sclerostin mRNA was not detected. Dexamethasone also increased Dkk-1 protein production by osteoblasts, whereas sclerostin protein was not detected. Bone formation might be impaired at least in the first week of the initiation of glucocorticoid therapy by increase of the serum Wnt signaling inhibitors; however, their reductions in the subsequent weeks were contradictory to the maintained suppression of the bone formation markers after glucocorticoid therapy for patients with systemic autoimmune diseases.Keywords
This publication has 45 references indexed in Scilit:
- WNT signaling in bone homeostasis and disease: from human mutations to treatmentsNature Medicine, 2013
- Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell ArteritisSeminars in Arthritis and Rheumatism, 2012
- Update on Wnt signaling in bone cell biology and bone diseaseGene, 2012
- Sclerostin: Current Knowledge and Future PerspectivesCalcified Tissue International, 2010
- Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cellsJournal of Bone and Mineral Research, 2010
- Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind studyOsteoporosis International, 2008
- Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective studyJournal of Bone and Mineral Metabolism, 2008
- Sclerostin is a delayed secreted product of osteocytes that inhibits bone formationThe FASEB Journal, 2005
- Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004)Journal of Bone and Mineral Metabolism, 2005
- Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosisBiochemical and Biophysical Research Communications, 2004